Kratom use in the United States has surged over the past decade. The herbal supplement — derived from the leaves of the Southeast Asian tree Mitragyna speciosa — is now sold in gas stations, smoke shops, and online retailers nationwide. Its active alkaloids bind to the same opioid receptors as codeine and morphine, producing effects that range from stimulation at low doses to sedation and pain relief at higher doses.
With kratom's rising popularity comes a question that millions of people are asking: does kratom show up on a drug screening?
The short answer is no — kratom does not appear on standard drug screening panels. But the full answer is far more nuanced, and the landscape is changing rapidly. This guide covers everything you need to know: which panels detect kratom, which do not, how long kratom stays in your system by specimen type, the legal status of kratom in 2026, why some employers are adding kratom to their testing programs, and what all of this means for both individuals and organizations.
The Quick Answer: Kratom Does Not Show Up on Standard Drug Screenings
If you are taking a standard 5-panel, 7-panel, 9-panel, or 10-panel drug screening, kratom will not be detected. Period.
Standard drug screening panels target the substance classes defined by SAMHSA (Substance Abuse and Mental Health Services Administration) and the Department of Transportation (DOT):
- Marijuana (THC)
- Cocaine
- Amphetamines / Methamphetamine
- Opiates (codeine, morphine, heroin)
- Phencyclidine (PCP)
Extended panels (7, 9, 10-panel) add substances like benzodiazepines, barbiturates, methadone, and methaqualone — but still do not include kratom. For a complete breakdown of what each panel covers, see our detailed guide: 5 Panel vs. 10 Panel Drug Screening: What Does Each Test Detect?
The reason is straightforward: kratom's active compounds — mitragynine and 7-hydroxymitragynine (7-OH) — are structurally distinct from the drug classes targeted by standard immunoassay screens. The antibodies in a standard drug test simply do not bind to kratom alkaloids. Even though mitragynine acts on opioid receptors, it is not an opiate, and it does not trigger cross-reactivity on opiate immunoassays at typical use concentrations.
When SAMHSA published its updated Mandatory Guidelines for Federal Workplace Drug Testing Programs in January 2025 (effective July 7, 2025), kratom was not included in either the urine or oral fluid authorized testing panels.
Will Kratom Show Up on a Drug Screening If Specifically Tested For?
Yes. While kratom does not appear on standard panels, it absolutely can be detected when a test specifically targets mitragynine and 7-hydroxymitragynine. Several major clinical laboratories now offer dedicated kratom assays:
Labcorp
Labcorp's test code 791750 screens for kratom using an immunoassay with a 5.0 ng/mL cutoff, followed by LC-MS/MS confirmation at 1.0 ng/mL for both mitragynine and 7-hydroxymitragynine. This is a urine-based test that must be specifically ordered — it is never included automatically in any standard panel.
Quest Diagnostics
Quest Diagnostics offers a quantitative mitragynine urine test using LC-MS/MS. Like Labcorp, this test is available only as a specific add-on — it is excluded from both Quest's Base and Extended panels.
ARUP Laboratories
ARUP Laboratories offers a kratom (mitragynine) screen with reflex to confirmation in urine, providing another option for employers and clinicians who want to include kratom in their testing program.
Aegis Sciences (Oral Fluid)
Aegis Sciences offers oral fluid kratom assays that detect mitragynine and 7-hydroxymitragynine, with a detection window of approximately minutes to 48 hours after use. This is notable because oral fluid testing is typically faster and more practical for on-site screening than laboratory-based urine tests.
The takeaway: kratom detection is available but never automatic. An employer, probation officer, or clinician must make a deliberate decision to add kratom to their testing panel. If they have not done so, kratom will not be detected regardless of how much or how recently you consumed it.
How Long Does Kratom Stay in Your System?
If you know that kratom is on your testing panel — or if you want to understand the pharmacokinetics for clinical or safety reasons — detection windows vary significantly by specimen type.
Detection Windows by Specimen
| Specimen Type | Detection Window | Notes |
|---|---|---|
| Urine | 1–9 days | Most common specimen for kratom testing. Occasional users: up to 5 days. Chronic heavy users: up to 9 days or slightly longer. |
| Oral fluid (saliva) | Minutes to 48 hours | Detects very recent use. Best for identifying current impairment or same-day use. |
| Blood | 24–48 hours | Short window. Primarily used to confirm recent use or active intoxication. |
| Hair | Up to 90 days | Longest window. Rarely used for kratom. Detection limits as low as 0.05 pg/mg for mitragynine. |
Factors That Affect Detection Time
Several individual variables influence how long kratom remains detectable:
Dosage and frequency. Higher doses and more frequent use lead to greater accumulation of metabolites, extending the detection window. A single low dose may clear from urine in 2–3 days, while daily heavy use can extend detection to a week or more.
Metabolism and body composition. Mitragynine is fat-soluble, meaning individuals with higher body fat percentages may retain the compound longer. Age, liver function, metabolic rate, and hydration level also play roles.
Kratom strain and form. Different kratom products contain varying concentrations of mitragynine and 7-hydroxymitragynine. Concentrated extracts and 7-OH products deliver significantly higher alkaloid loads than raw leaf powder, potentially extending detection times.
Specimen type. As shown in the table above, the detection window varies dramatically by specimen — from hours (blood) to months (hair). Understanding which specimen your test uses is essential for estimating your personal detection window.
For a broader understanding of how drug screening timelines work across all substances, see: How Long Does a Drug Screening Take to Get Results?
Kratom Pharmacology: Why Standard Drug Tests Miss It
To understand why kratom slips through standard screening, it helps to understand its pharmacology.
Kratom contains over 50 alkaloids, but two dominate its psychoactive profile:
Mitragynine accounts for approximately 66% of the alkaloid content in kratom leaves. It is a partial agonist at mu-opioid receptors — the same receptors targeted by morphine, heroin, and prescription opioids. However, mitragynine's molecular structure is fundamentally different from classical opiates. It belongs to the indole alkaloid family, not the morphinan family. This structural difference is exactly why opiate immunoassays do not cross-react with it.
7-Hydroxymitragynine (7-OH) is present in much smaller quantities but is approximately 13 times more potent than morphine at the mu-opioid receptor. It is the primary driver of kratom's sedative and analgesic effects at higher doses.
Beyond opioid receptors, mitragynine also interacts with serotonin, dopamine, norepinephrine, and kappa-opioid receptor systems — giving kratom a complex pharmacological profile that does not fit neatly into any single drug class. This multi-receptor activity is why the National Institute on Drug Abuse (NIDA) continues to fund research on kratom's mechanisms, and why standard drug screening panels, which are designed to detect specific drug classes, miss it entirely.
This is also why specialized kratom tests use specific immunoassays calibrated to mitragynine's unique molecular signature, rather than relying on the broad-class antibodies used in standard drug screens. For more on how initial screening and confirmatory testing work at a molecular level, see: Initial Drug Testing vs. Confirmatory Drug Testing.
The Legal Status of Kratom in 2026
Kratom's legal status is a patchwork — federally unscheduled but banned or restricted in several states. This ambiguity directly affects whether employers can and should test for it.
Federal status
Kratom remains legal at the federal level as of April 2026. The DEA listed kratom as a "Drug and Chemical of Concern" but has not scheduled it under the Controlled Substances Act. In 2016, the DEA announced intent to place mitragynine and 7-hydroxymitragynine in Schedule I on an emergency basis, but withdrew the notice after significant public and congressional pushback.
The FDA has taken a different approach, positioning kratom as an unapproved new dietary ingredient and issuing multiple warnings about safety risks. In July 2025, the FDA recommended that certain concentrated 7-OH products be placed in Schedule I — but as of April 2026, the DEA has not completed the rulemaking to make this effective.
States where kratom is banned
As of April 2026, six states have completely banned kratom:
- Alabama — Classified as a Schedule I substance
- Arkansas — Classified as a Schedule I substance
- Indiana — Classified as a synthetic drug
- Vermont — Banned by statute
- Louisiana — Banned effective 2024
- Wisconsin — Mitragynine and 7-hydroxymitragynine classified as Schedule I
Rhode Island previously banned kratom but signed the Kratom Consumer Protection Act in July 2025, with regulated sales taking effect April 1, 2026.
States with regulatory frameworks
Many states have adopted Kratom Consumer Protection Acts (KCPAs) that regulate rather than ban the substance — imposing age restrictions (typically 21+), labeling requirements, contamination testing, and limits on 7-OH concentration. These regulatory frameworks reflect a middle path between outright prohibition and unregulated access.
What the legal patchwork means for testing
For employers: if you operate in a state where kratom is banned, you have a stronger legal basis — and arguably an obligation — to include kratom in your testing program. In states where kratom is legal and unregulated, the decision to test is discretionary and should be based on your industry's safety profile and risk assessment.
Why Some Employers Are Adding Kratom to Their Drug Screening Panels
Despite kratom's absence from standard panels and federal testing mandates, a growing number of employers are proactively adding kratom testing — particularly in safety-sensitive industries.
The safety case
Kratom acts on opioid receptors and can produce sedation, impaired motor coordination, dizziness, and drowsiness — effects that are incompatible with operating vehicles, heavy machinery, or performing safety-critical tasks. According to DISA Global Solutions, the growing market for concentrated 7-OH products makes this concern more acute, as these products deliver significantly stronger opioid-like effects than traditional kratom leaf.
The detection gap
Because kratom does not appear on standard panels, an employee could be significantly impaired by kratom and pass a routine drug screening — creating a false sense of security for the employer. This gap is particularly concerning in industries where impairment has life-or-death consequences: transportation, construction, manufacturing, healthcare, and emergency services.
The regulatory trajectory
With the FDA actively pursuing scheduling of concentrated 7-OH products and several states banning or restricting kratom, the regulatory trend points toward tighter control. Employers who add kratom testing now are ahead of the curve if federal scheduling eventually occurs.
How to add kratom to your screening program
Adding kratom testing is administratively straightforward. Employers can:
- Request a kratom add-on from their testing laboratory (Labcorp, Quest, ARUP, or others).
- Update their drug-free workplace policy to specify that kratom is a tested substance.
- Use non-NIDA (non-standard) testing panels that include kratom alongside other expanded substances. For more on this, see: Non-NIDA Drug Screen: What It Means and Why It Matters.
- Deploy on-site screening technology with customizable substance panels. Portable drug screening devices with configurable detection parameters allow organizations to adapt their panels as the regulatory landscape evolves — without replacing hardware or restructuring their program.
Kratom and Different Drug Screening Methods
The method of drug screening affects both whether kratom can be detected and the practical implications of the result.
Urine screening for kratom
Urine is the most common specimen for laboratory-based kratom testing. The detection window (1–9 days) captures both recent and moderately past use. However, urine screening for kratom shares the same limitations as urine screening for any substance: susceptibility to adulteration and specimen tampering, the need for a private collection facility, and poor correlation between urine concentration and actual impairment at the time of the test.
Oral fluid screening for kratom
Oral fluid (saliva) kratom screening is emerging as a faster, more practical alternative for on-site testing. The detection window (minutes to 48 hours) is shorter than urine but optimized for detecting recent or active use — which is precisely what matters in safety-critical contexts.
Oral fluid collection is non-invasive, observed (virtually eliminating cheating), and can be performed anywhere. For organizations using portable oral fluid screening technology, customizable substance panels offer the flexibility to include or exclude kratom as policies and regulations evolve. For a deeper comparison of the two methods, see: Saliva vs. Urine Drug Test: Which Method Is Right for You?
Hair testing for kratom
Hair testing provides the longest detection window (up to 90 days) but is rarely used for kratom specifically. Research published in PMC (National Library of Medicine) confirms that hair-based kratom detection is validated and technically feasible, with detection limits as low as 0.05 pg/mg for mitragynine, but practical application remains limited to forensic and clinical pathology contexts.
Blood testing for kratom
Blood testing for kratom is limited to forensic investigations and acute clinical care. The 24–48 hour detection window makes it unsuitable for routine screening.
Can Kratom Cause a False Positive for Other Drugs?
This is a common concern, and the evidence provides reassurance: kratom is very unlikely to cause a false positive on standard drug screening panels.
Because mitragynine's molecular structure is fundamentally different from opiates, amphetamines, benzodiazepines, and other targeted drug classes, it does not typically cross-react with standard immunoassays. Published research confirms that cross-reactivity between kratom alkaloids and standard opiate immunoassay screens is negligible at normal consumption levels.
However, there are rare and anecdotal reports of kratom triggering false positives on certain opiate screens — particularly older or less specific immunoassay platforms. If you receive an unexpected positive result after using kratom, you should request confirmatory testing via GC-MS or LC-MS/MS, which will definitively identify the specific compounds present and rule out kratom-related cross-reactivity.
For a broader understanding of what causes false positives and how confirmatory testing eliminates them, see: What Is Drug Screening? The Complete Guide for 2026.
Kratom Safety: What the FDA and Medical Experts Say
While this article focuses on drug screening, it is important to understand the safety context surrounding kratom — both for individuals making personal health decisions and for employers evaluating whether to include kratom in their testing programs.
FDA position
The FDA has issued multiple warnings about kratom, citing risks of liver toxicity, seizures, respiratory depression, and substance use disorder. In 2025, the FDA issued seven warning letters to companies marketing concentrated 7-OH products, and recommended that certain high-potency 7-OH formulations be placed in Schedule I.
Health risks
According to the Mayo Clinic, kratom has been linked to serious adverse effects including nausea and vomiting, seizures, liver damage, respiratory depression, physical dependence and withdrawal, and psychosis in some cases. The CDC linked kratom to 152 deaths in 2016–2017, though polysubstance use was involved in 87% of these cases.
The 7-OH escalation
The emergence of concentrated 7-hydroxymitragynine (7-OH) products — shots, gummies, and extracts marketed for their potency — has escalated safety concerns. These products deliver alkaloid concentrations far exceeding those found in traditional kratom leaf, and are associated with reports of respiratory depression, seizures, and fatalities. This trend is a significant driver behind the growing interest in workplace kratom testing.
What to Do If You Use Kratom and Face a Drug Screening
If you use kratom and are scheduled for a drug screening, here is a practical framework:
1. Determine what panel you are being tested on. Ask the employer, testing provider, or requesting party what specific panel is being used. If it is a standard 5, 7, 9, or 10-panel, kratom will not be detected.
2. Check whether kratom has been added as a custom test. Some employers, particularly in safety-sensitive industries or states where kratom is banned, specifically add kratom to their panels. If you are unsure, you may ask — there is no legal prohibition against inquiring about the scope of a drug test.
3. Understand your detection window. If kratom testing is on the panel, refer to the detection windows above. For urine, the typical window is 1–9 days depending on usage frequency. For oral fluid, the window is up to 48 hours.
4. Be prepared for the MRO interview. If your test includes kratom and returns a positive result, a Medical Review Officer (MRO) may contact you. Unlike prescription medications (where a valid prescription can explain a positive result), kratom does not have an established medical-use defense in most jurisdictions. The MRO's role is to verify the result, not to evaluate the legality of kratom in your state.
5. Know your rights regarding inconclusive results. If the initial screen is positive but the confirmatory test is negative or inconclusive, you should not face adverse consequences. Confirmatory LC-MS/MS testing is the gold standard and should always be the basis for any employment or legal decision.
The Future of Kratom Drug Testing
The kratom testing landscape is evolving along several clear vectors:
Expanded employer adoption. As concentrated 7-OH products proliferate and kratom-related incidents accumulate, more employers — especially in safety-sensitive industries — are proactively adding kratom to their panels. This trend will accelerate if the DEA completes scheduling of 7-OH products.
Potential federal scheduling. The FDA's July 2025 recommendation to schedule certain 7-OH products in Schedule I signals a clear regulatory trajectory. If this rulemaking is completed, kratom (or at least 7-OH) could be added to federally mandated testing panels, fundamentally changing the answer to "does kratom show up on a drug screening" from "only if specifically tested" to "yes, on all standard panels."
Improved detection technology. As kratom testing demand grows, laboratory and point-of-care technology will evolve to meet it. Modern portable drug screening devices with configurable and updatable substance panels are already positioned to adapt when kratom is added to standard or custom panels — delivering on-site results without waiting for laboratory turnaround.
Point-of-care oral fluid kratom testing. The development of on-site oral fluid kratom assays (like those from Aegis) points toward a future where kratom can be screened at the point of collection — at a workplace, roadside, healthcare facility, or fire station — with the same speed and convenience as screening for any other substance.
Frequently Asked Questions
Does kratom show up on a 5-panel drug screening?
No. A standard 5-panel drug screening tests for marijuana, cocaine, amphetamines, opiates, and PCP. Kratom's alkaloids (mitragynine and 7-hydroxymitragynine) are not detected by any of these assays.
Does kratom show up on a 10-panel drug screening?
No. A 10-panel drug screening adds benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone to the standard 5-panel — but still does not include kratom.
Will kratom show up on a DOT drug screening?
No. DOT drug screening follows SAMHSA-mandated panels, which do not include kratom. Even the updated panels (effective July 2025) that added fentanyl do not include kratom alkaloids.
Can kratom make me fail a drug test for opiates?
This is extremely unlikely. While mitragynine acts on opioid receptors, its molecular structure is different from classical opiates, and cross-reactivity with opiate immunoassays is negligible at typical use levels. If you are concerned, request confirmatory GC-MS or LC-MS/MS testing to definitively identify the compound.
How long after using kratom will I test clean on a urine test?
For occasional users (once or twice per week), kratom is typically undetectable in urine within 3–5 days. For daily or heavy users, detection may extend to 7–9 days. Individual factors like metabolism, body fat percentage, and hydration level affect this timeline.
Do employers drug test for kratom?
Most do not — yet. Standard employer drug screening panels exclude kratom. However, a growing number of employers in safety-sensitive industries (transportation, construction, healthcare, manufacturing) are adding kratom as a custom panel. If you are uncertain, ask your employer or review the drug-free workplace policy.
Is kratom legal in my state?
As of April 2026, kratom is banned in six states: Alabama, Arkansas, Indiana, Vermont, Louisiana, and Wisconsin. It is legal but regulated in many others. Check your state's current laws, as the landscape is evolving rapidly. See the Congressional Research Service overview for a federal perspective.
Should my organization start testing for kratom?
Consider adding kratom testing if: you operate in a state where kratom is banned, your workforce includes safety-sensitive roles, you have experienced kratom-related incidents, or your risk assessment indicates exposure to concentrated 7-OH products. Consult with your testing provider and legal counsel to determine the best approach for your specific situation.